Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals